Origin Bancorp (NYSE: OBK) experienced a 32.2% increase in short interest in March, reaching 570,732 shares, which represents about 1.9% of outstanding shares and a 3.1 days-to-cover ratio. The stock is currently trading near a 12-month high with a market cap of $1.42 billion, a P/E of 19.12, and recently beat earnings estimates. Analysts have a "Moderate Buy" rating with a $46.67 consensus price target, and institutional investors have been increasing their holdings.

Sysco (NYSE:SYY) has announced an increase in its quarterly cash dividend to $0.55 per share, up $0.01 from the previous $0.54. This dividend is payable on July 24, 2026, to shareholders of record as of July 2, 2026. The company stated that this action reinforces its Dividend Aristocrat status and includes plans for a $0.04 annual dividend increase for fiscal year 2027.

Sysco Corp. (NYSE: SYY) has announced a 1.9% increase in its quarterly dividend to $0.55 per share, up from $0.54. This results in an annualized dividend of $2.2 and an annual yield of 2.9 percent. The dividend is payable on July 24, 2026, to stockholders of record on July 2, 2026, with an ex-dividend date of July 1, 2026.

Regions Financial reported slightly disappointing first-quarter results with a sequential decline in net interest income, but maintained its full-year outlook. Morningstar plans to increase its fair value estimate for Regions stock due to a higher leverage ratio forecast stemming from new bank regulations, assessing shares as undervalued. The bank's granular deposit base and primary bank relationships in rural markets provide sticky retail deposits despite intense competition in other areas.

Adobe Inc. director Cristiano R. Amon reported routine equity compensation changes. He received a new grant of 1,367 restricted stock units (RSUs) after 900 RSUs vested and converted into common stock. Following these transactions, Amon directly holds 1,822 shares of common stock and 1,367 unvested RSUs.

Adobe Inc. director Dheeraj Pandey recently reported equity activity, including the vesting of 900 Restricted Stock Units (RSUs) which converted into an equivalent number of common shares on April 15, 2026. Concurrently, he received a new grant of 1,367 RSUs, set to vest completely on the date of Adobe's next annual stockholders' meeting. Following these transactions, Pandey holds 5,920 direct shares of common stock and 1,367 unvested RSUs.

Jacobs Solutions Inc. (J) is projected to report a diluted profit of $1.64 per share for Q2 2026, marking a 14.7% increase year-over-year. Analysts forecast continued earnings growth for the full fiscal years 2026 and 2027, with a "Moderate Buy" consensus rating and a potential 24.3% upside from current market levels. Despite strong earnings performance, the stock's 52-week gain of 8.3% has trailed broader market indices like the S&P 500 and the State Street Industrial Select Sector SPDR ETF.

Bexar County school districts are joining a class action lawsuit against major social media companies, alleging that platforms like Facebook, Instagram, Snapchat, TikTok, and YouTube harm students and burden districts with mental health costs. While recent verdicts against these companies suggest potential for significant damages, legal experts express skepticism about their longevity on appeal due to Section 230 protections. The article argues that the true value of these lawsuits may lie in raising public awareness and driving societal change, similar to past actions against the tobacco industry, rather than solely focusing on legal liability.

Lockheed Martin Space has been awarded an $850.4 million contract for continued work on the Trident II nuclear missile. More than half of the work for this contract will be performed at the company's headquarters in Jefferson County, Colorado. The deal was announced by the Pentagon.

Moderna announced it will present promising Phase 1/2 data for its investigational cancer antigen therapy mRNA-4359 in combination with pembrolizumab as a first-line treatment for advanced melanoma at the 2026 AACR Annual Meeting. The study showed an 83% overall response rate and a 92% disease control rate among 12 participants, with a manageable safety profile. The U.S. FDA has granted Fast Track designation for this combination therapy for checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1+ tumors.